PYC Therapeutics (PYC) Short Interest
PYC Therapeutics (ASX:PYC) had 0.14% of shares reported as short positions as of 24 Aug 2026, representing 1,418,090 shares. PYC Therapeutics operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
PYC Therapeutics
PYC Therapeutics is a clinical-stage biotech company focused on developing RNA therapies to address genetic diseases. Their proprietary RNA delivery platform aims to provide safer and more effective treatments by targeting the underlying causes of these diseases. The company is advancing a pipeline of novel therapies for eye, central nervous system, and kidney diseases.
Short position
PYC Therapeutics (ASX:PYC) has 0.14% of its shares on issue reported as short positions as of 24 Aug 2026, or about 1,418,090 shares. Over the past 30 days that figure has fallen 0.14 percentage points, and over 90 days it has been broadly flat. Its highest recorded short interest was 0.42% in January 2026. PYC is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Weekly context: The 10 most shorted ASX stocks — Week 35, 2026.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4PYC intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links
Short interest history & FAQ
Company
AI-generated research profile of Pyc Therapeutics
About
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Be the first to discuss PYC
Start a research thread or post the first pulse update